Atopic dermatitis differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Line 85: | Line 85: | ||
* Delayed-type hypersensitivity response | * Delayed-type hypersensitivity response | ||
* Skin inflammation mediated by hapten-specific T cells | * Skin inflammation mediated by hapten-specific T cells | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |Any | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" |May be multiple | * Contact with allergens in the past 1-2 days | ||
* Positive family history | |||
| align="center" style="background:#F5F5F5;" |May be multiple after 1-2 days of exposure | |||
| align="center" style="background:#F5F5F5;" | Erythematous well-demarcated papules | | align="center" style="background:#F5F5F5;" | Erythematous well-demarcated papules | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Surrounding the area in contact with the offending agent | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
Line 97: | Line 99: | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Stinging and burning | * Stinging and burning | ||
| align="center" style="background:#F5F5F5;" |Nl | * Localized swelling | ||
* Lichenified pruritic plaques | |||
| align="center" style="background:#F5F5F5;" |Nl to ↑ | |||
(Eosinophilia) | |||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 109: | Line 114: | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | NA | | align="center" style="background:#F5F5F5;" | NA | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |NA | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Clinical manifestation + [[Patch test (medicine)|patch test]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* | * Prevention by avoidance | ||
|- | |- | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Irritant contact dermatitis]]<ref name="pmid30293200">{{cite journal |vauthors=Bains SN, Nash P, Fonacier L |title=Irritant Contact Dermatitis |journal=Clin Rev Allergy Immunol |volume= |issue= |pages= |date=October 2018 |pmid=30293200 |doi=10.1007/s12016-018-8713-0 |url=}}</ref> | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Irritant contact dermatitis]]<ref name="pmid30293200">{{cite journal |vauthors=Bains SN, Nash P, Fonacier L |title=Irritant Contact Dermatitis |journal=Clin Rev Allergy Immunol |volume= |issue= |pages= |date=October 2018 |pmid=30293200 |doi=10.1007/s12016-018-8713-0 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Activation of the innate immune system by the pro-inflammatory properties of chemicals | * Activation of the innate immune system by the pro-inflammatory properties of chemicals | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |Any, more occupational exposure | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Cumulative exposure to irritants | * Cumulative exposure to irritants | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |Usually single immediately after the exposure | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | Any area in contact with the irritant | | align="center" style="background:#F5F5F5;" | Any area in contact with the irritant | ||
Line 142: | Line 147: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | Clinical manifestation | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Negative hypersensitivity tests | |||
|- | |- | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Seborrheic dermatitis]] | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Seborrheic dermatitis]] |
Revision as of 18:22, 12 October 2018
Atopic dermatitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Atopic dermatitis differential diagnosis On the Web |
American Roentgen Ray Society Images of Atopic dermatitis differential diagnosis |
Risk calculators and risk factors forAtopic dermatitis differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Differentiating Atopic Dermatitis from other Diseases
Category | Diseases | Etiology | Inherited | Acquired | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Demography | History | Symptoms | Physical examination | |||||||||||||||||||||||||
Lab Findings | Imaging | Histopathology | ||||||||||||||||||||||||||
Appearance | Itching | Bleeding | Fever | BP | Tenderness | Nail pitting | Other | CBC | ESR/CRP | Electrolytes | BUN/Cr | LFT | ||||||||||||||||
Single/
Multiple |
Rash | Involved areas | Pustule | WBC | Hb | Plt | ||||||||||||||||||||||
Skin disorders | Atopic dermatitis | |||||||||||||||||||||||||||
Allergic contact dermatitis[1] |
|
– | + | Any |
|
May be multiple after 1-2 days of exposure | Erythematous well-demarcated papules | Surrounding the area in contact with the offending agent | – | + | – | – | Nl | + | – |
|
Nl to ↑
(Eosinophilia) |
Nl | Nl | Nl | Nl | Nl | Nl | NA | NA | Clinical manifestation + patch test |
| |
Irritant contact dermatitis[2] |
|
– | + | Any, more occupational exposure |
|
Usually single immediately after the exposure | Any area in contact with the irritant | Clinical manifestation |
| |||||||||||||||||||
Seborrheic dermatitis | Any, onset during the 1st days or weeks of life | Greasy scaling on a yellow-red base | Scalp, axilla, and diaper area | – | ||||||||||||||||||||||||
Psoriasis | ||||||||||||||||||||||||||||
Lichen simplex chronicus | ||||||||||||||||||||||||||||
Ichthyosis vulgaris | ||||||||||||||||||||||||||||
Nummular dermatitis | ||||||||||||||||||||||||||||
Netherton's syndrome | ||||||||||||||||||||||||||||
Dubowitz syndrome | ||||||||||||||||||||||||||||
Erythrokeratodermia variabilis | ||||||||||||||||||||||||||||
Diseases | Etiology | Inherited | Acquired | Demography | History | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | BP | Tenderness | Nail pitting | Other | WBC | Hb | Plt | ESR/CRP | Electrolytes | BUN/Cr | LFT | Imaging | Histopathology | Gold standard | Additional findings | |
Infection | Dermatophytes | |||||||||||||||||||||||||||
Candida | ||||||||||||||||||||||||||||
Herpes simplex | ||||||||||||||||||||||||||||
Staphylococcus aureus | ||||||||||||||||||||||||||||
Molluscum contagiosum | ||||||||||||||||||||||||||||
Scabies |
|
Multiple | Erythematous papular lesions | Flexor wrists, finger webs and genitalia | +++ | |||||||||||||||||||||||
HIV | ||||||||||||||||||||||||||||
Diseases | Etiology | Inherited | Acquired | Demography | History | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | BP | Tenderness | Nail pitting | Other | WBC | Hb | Plt | ESR/CRP | Electrolytes | BUN/Cr | LFT | Imaging | Histopathology | Gold standard | Additional findings | |
Immunologic disorders | Dermatitis herpetiformis | |||||||||||||||||||||||||||
Pemphigus foliaceus | ||||||||||||||||||||||||||||
Graft-versus-host disease | ||||||||||||||||||||||||||||
Dermatomyositis | ||||||||||||||||||||||||||||
Immune deficiency | Wiskott-Aldrich syndrome | |||||||||||||||||||||||||||
Hyper-IgE syndrome | ||||||||||||||||||||||||||||
DiGeorge syndrome | ||||||||||||||||||||||||||||
Severe combined immunodeficiency (SCID) | ||||||||||||||||||||||||||||
Ataxia telangiectasia | ||||||||||||||||||||||||||||
Diseases | Etiology | Inherited | Acquired | Demography | History | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | BP | Tenderness | Nail pitting | Other | WBC | Hb | Plt | ESR/CRP | Electrolytes | BUN/Cr | LFT | Imaging | Histopathology | Gold standard | Additional findings | |
Metabolic Diseases | Phenylketonuria | |||||||||||||||||||||||||||
Tyrosinemia | ||||||||||||||||||||||||||||
Histidinemia | ||||||||||||||||||||||||||||
Multiple carboxylase deficiency | ||||||||||||||||||||||||||||
Nutritional deficiencies | Zinc deficiency | |||||||||||||||||||||||||||
Niacin (B3) deficiency | ||||||||||||||||||||||||||||
Pyridoxine (B6) deficiency | ||||||||||||||||||||||||||||
Biotin (B7) deficiency | ||||||||||||||||||||||||||||
Malignancy | Mycosis fungoides | |||||||||||||||||||||||||||
Histiocytosis X | ||||||||||||||||||||||||||||
Medications | Infliximab | |||||||||||||||||||||||||||
Category | Diseases | Etiology | Inherited | Acquired | Demography | History | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | BP | Tenderness | Nail pitting | Other | WBC | Hb | Plt | ESR/CRP | Electrolytes | BUN/Cr | LFT | Imaging | Histopathology | Gold standard | Additional findings |
References
- ↑ Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF (2009). "Allergic and irritant contact dermatitis". Eur J Dermatol. 19 (4): 325–32. doi:10.1684/ejd.2009.0686. PMID 19447733.
- ↑ Bains SN, Nash P, Fonacier L (October 2018). "Irritant Contact Dermatitis". Clin Rev Allergy Immunol. doi:10.1007/s12016-018-8713-0. PMID 30293200.